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FasApoptosis is a major mechanism regulating immune tolerance by the elimination of autoreactive T lymphocytes.
A failure of activation induced cell-death (AICD) has been described in T lymphocytes frompatientswithmultiple
sclerosis (MS). The aims of this studywere to evaluate AICD in T lymphocytes from patients withMS and healthy
controls, and to explore themolecularmechanisms underlying the deregulation observed in apoptosis induction.
PHA-induced AICD was reduced in T lymphocytes from patients with relapsing–remitting MS compared with
controls. This ﬁnding was associated with a diminished expression of Fas and a failure in caspase 3 activation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is an autoimmune disease affecting the cen-
tral nervous system and a leading cause of neurological disability in
young adults. Development of MS appears to be associatedwith activat-
ed T cells attackingmyelin antigens, which results in demyelination and
axonal damage (McFarland and Martin, 2007; Comabella and Khoury,
2012). A number of mechanisms have been described to maintain im-
munehomeostasis and avoid the development of autoimmunediseases.
One such mechanism is activation-induced cell death (AICD), a form of
programmed cell death or apoptosis. In AICD, T cells die in a controlled
manner by the activation of the T cell receptor and through the Fas sig-
naling pathway (Pender, 1999; Zhang et al., 2004). Deregulation of this
process has been linked to the development of autoimmunediseases in-
cluding MS.
It has been reported that T cells from MS patients respond less
strongly to apoptotic stimuli than those from healthy controls (HCs)SS, Expanded Disability Status
peripheral blood mononuclear
ve multiple sclerosis; RRMS, re-
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bella).(Macchi et al., 1999; Comi et al., 2000), and T-cell apoptosis has also
been associated with disease activity (Okuda et al., 2006). Little is
known, however, about a potentially different apoptotic behavior of
the different clinical forms of MS. The objectives of the present study
were to evaluate spontaneous apoptosis and AICD in T cells from HC
and MS patients with different clinical forms and activity phases of the
disease; and to unravel the molecular mechanisms underlying the dif-
ferences in apoptosis induction observed in T cells from MS patients.
2. Materials and methods
2.1. Patients
Twelve HCs and 36 untreated patients who satisﬁed the 2010
McDonald's criteria for clinically deﬁnite MS (Polman et al., 2011)
were included in the study. The MS group comprised 17 patients with
relapsing–remitting MS (RRMS) in clinical remission, 6 RRMS patients
in relapse and 13 patients with primary progressive MS (PPMS). In
RRMS patients in relapse, blood samples were collected before treat-
ment with corticosteroids. Neurological disability at the time of blood
collection was evaluated by the Expanded Disability Status Scale
(EDSS) (Kurtzke, 1983). The studywas approved by the Ethics Commit-
tee of Vall d'Hebron University Hospital and subjects gave written in-
formed consent. Demographic and clinical characteristics of MS
patients and healthy controls (HCs) are summarized in Table 1.
Table 1
Demographic and clinical characteristics of MS patients and HC included in the study.
Characteristics HC MSa PPMS RRMS Relapses
N 12 30 13 17 6
Female/male (% women) 8/4 (66.7) 20/10 (66.7) 8/5 (61.5) 12/5 (70.6) 5/1 (83.3)
Age (years) 41.4 (10.2) 44.3 (8.4) 50.0 (9.2) 40.4 (5.6) 41.8 (7.3)
Duration of disease (years) – 11.6 (6.9) 13.1 (7.6) 11.0 (6.5) 12.5 (8.8)
EDSS – 3.4 (2.7) 6.4 (1.7) 1.5 (1.0) 3.0 (1.4)
Number of relapses in the 2 previous years – 0.5 (0.6) – 0.5 (0.6) 0.7 (1.2)
Data are expressed as mean (standard deviation). EDSS: Expanded Disability Status Scale. HC: healthy control. RRMS: relapsing–remitting multiple sclerosis. PPMS: primary progressive
multiple sclerosis. Relapses: RRMS patients during acute relapses.
a MS: refers to the whole MS group without including RRMS patients in relapse.
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Peripheral blood was collected in cell preparation tubes (CPTs)
(Beckton Dickinson, BD, New Jersey, USA). PBMC were obtained with
the Ficoll–Hypaque density gradient method within 2 h from sampling.
Cells were resuspended in a culture medium composed of RPMI 1640
supplemented with 10% fetal bovine serum, 4 mM L-glutamine,
25 mM HEPES buffer, 50 U/ml penicillin, and 50 μg/ml streptomycin
(GIBCO-Life technologies, Carlsbad, CA), counted and cultured at a den-
sity of 2 million cells/ml in 24-well plates (1 ml per well). To induce
AICD, cells were stimulated with phytohemagglutinin (PHA; Sigma-
Aldrich, St. Louis, MO) at a concentration of 10 μg/ml for 20 h. This con-
centration and timepointwere considered optimal after AICD optimiza-
tion experiments carried out by the group.
2.3. Determination of Fas expression by ﬂow cytometry
Freshly isolated PBMCwere washed twice with PBS and blocked for
10min at room temperature in blocking solution (PBS with 10% of fetal
bovine serum). Cells were then incubated with speciﬁc antibodies for
25 min at room temperature with shaking. The following antibodies
were used: phycoerythrin (PE)-conjugated anti-human Fas or PE-
isotype control, ﬂuorescein isothiocyanate (FITC)-conjugated anti-
human CD3 or FITC-isotype control (BD). Cells were then washed
twice with PBS and analyzed on a dual laser FACSCanto (BD) ﬂow
cytometer equipped with FACSDiva software. Lymphocytes were
gated based on forward and side scatters and CD3was used as a marker
of T-lymphocytes. Gating strategy is shown in Supplementary Fig. 1.
2.4. Evaluation of apoptosis by ﬂow cytometry
After 20 h of culture, cells were collected, washed twice with PBS,
blocked for 10 min at room temperature (PBS with 10% fetal bovine
serum) and incubated with antibodies for 25 min at room temperature
with shaking. PE-conjugated anti-human CD3 (BD), APC-conjugated
anti-human CD4 (eBioscience, San Diego, CA) and CD8 (Biolegend, San
Diego, CA) or their PE-isotype control (BD) and APC-isotype control
(eBioscience) antibodies were used. Subsequently, cells were washed
with annexin V binding buffer (BD) and FITC-conjugated annexin V
(BD) was added and incubated for 15 min at room temperature with
shaking. Cells were then washed twice with binding buffer and ana-
lyzed with the FACSCanto ﬂow cytometer. Annexin V positive cells
were considered apoptotic cells. Finally, 7-aminoactinomycin D (7-
AAD)was added to the cells. Gating strategy is shown in Supplementary
Fig. 1. Activation-induced cell death was determined by subtraction of
the percentage of T lymphocytes undergoing spontaneous apoptosis
from the total percentage of T lymphocytes in apoptosis after PHA
stimulation.
2.5. Protein extraction and caspase 3 western blot analysis
After 20 h of culture, the cells were collected andwashed twicewith
PBS. Whole cell extracts were obtained in RIPA lysis buffer containingprotease inhibitors. Ten micrograms of protein was loaded onto 15%
SDS acrylamide gels, electrophoresis was carried out, and proteins
were blotted onto nitrocellulosemembranes. Membranes were blocked
for 1 h in TBST buffer with 5% nonfatmilk, and incubated with a speciﬁc
antibody recognizing both the full and cleaved forms of caspase 3 (Cell
Signaling, Beverly, MA) at a 1:1000 dilution in TBST buffer with 3%
milk overnight at 4 °Cwith shaking. Afterwashing,membraneswere in-
cubated with horseradish peroxidase-conjugated secondary antibody.
Proteins were detected by enhanced chemiluminescence reagent
(Millipore, Billerica,MA). For analysis ofβ-actin expression,membranes
were stripped with a commercial stripping buffer (Millipore) and
stained with a β-actin antibody (Sigma-Aldrich) using the same condi-
tions as caspase 3 staining. Quantiﬁcation of protein expressionwas car-
ried out using the Science Lab Image Gauge software (Fujiﬁlm, Tokyo,
Japan). Nine samples were analyzed for each group.2.6. Statistical analysis
Statistical analysis was performed with the SPSS 17.0 package (SPSS
Inc, Chicago, IL). Student's t-testwas used to compare variables between
groups. Linear associations between apoptosis or Fas expression and
clinical variables were assessed by the Pearson correlation coefﬁcient.
Results were considered statistically signiﬁcant when p b 0.05.3. Results
3.1. AICD is decreased in T cells from RRMS patients
To evaluate AICD in T cells, PBMC were cultured in the presence or
absence of PHA and annexin V was used as a marker of apoptosis. In
the presence of PHA, AICD was decreased in the whole MS group
when compared with the HC group, as shown by the lower percentage
of annexin V positive T cells (mean values: 28.9% and 36.7% in MS pa-
tients and HC respectively; Fig. 1A); however, differences did not
reach statistical signiﬁcance (p = 0.122). Further stratiﬁcation of the
MS group into different clinical forms revealed a statistically signiﬁcant
decrease in AICD in RRMS patients in remission compared with HC
(mean values: 36.7% in HC and 26.5% in RRMS in remission; p = 0.04)
(Fig. 1A). A representative ﬂow cytometry staining of a HC and a patient
with RRMS is shown in Supplementary Fig. 1. The percentage of annexin
V positive T cells did not signiﬁcantly differ between PPMS patients and
RRMS patients in remission and HC (32.3, 26.5 and 36.7% respectively).
Likewise, AICD was comparable between RRMS patients in clinical re-
mission and RRMS patients whose blood was extracted at the time of
acute exacerbations (26.5 and 33.2% respectively). In the absence of
PHA, spontaneous apoptosis was similar between the whole MS group
or different clinical forms of the disease and HC and between RRMS pa-
tients in clinical remission and RRMS patients in relapse (15.5 for HC,
18.0 for the whole MS group, 17.8 for RRMS patients in remission,
18.3 for PPMS patients and 13.6% for RRMS patients in relapse). Both
spontaneous apoptosis and AICD were also evaluated in the CD4 and
CD8 subsets of T cells. Interestingly, AICD was signiﬁcantly reduced in
Fig. 1. Dot plots showing AICD in T cells (A) and CD8 T cells (B) fromMS patients and HC.
AICD results from the subtraction of the percentage of T lymphocytes undergoing sponta-
neous apoptosis from the total percentage of T lymphocytes in apoptosis after PHA stim-
ulation. *p b 0.05 in RRMS patients in respect to HC. HC: healthy control. RRMS:
relapsing–remittingMS patients in clinical remission. PPMS: primary progressivemultiple
sclerosis.
Fig. 2. Dot plots showing Fas expression in freshly isolated T cells from HC and the whole
MS group (A), different clinical forms of MS (B), RRMS patients in clinical remission and
RRMS patients in relapse (C). *p = 0.02 in the whole MS group versus HC. **p = 0.001
in RRMS patients in clinical remission versus HC. MS: whole group of MS patients exclud-
ing RRMS patients in relapse. HC: healthy control. RRMS: relapsing–remittingMS patients
in clinical remission. PPMS: primary progressive multiple sclerosis. Relapses: RRMS pa-
tients during acute relapses.
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RRMS in remission; p = 0.01) (Fig. 1B and Table 2).
Therewere no signiﬁcant correlations betweenAICDor spontaneous
apoptosis and clinical variables such as EDSS, number of relapses in the
two previous years, and disease duration (data not shown).
3.2. Fas expression is reduced in T cells from MS patients
Insomuch as Fas is themain death receptor mediating AICD, we ﬁrst
investigated Fas receptor expression in T cells fromMS patients and HC.
As shown in Fig. 2A, comparisons between thewhole MS group and the
HC group revealed a statistically signiﬁcant reduction of Fas expression
in T cells fromMS patients comparedwith controls (mean values: 76.0%
in HC versus 68.4% in MS patients, p = 0.02). In MS patients classiﬁed
according to their clinical forms, Fas expression was signiﬁcantly
lower in T cells from RRMS patients in remission compared with HCTable 2
Spontaneous apoptosis and AICD in CD4+ and CD8+ T cell subsets in different clinical
forms of MS and healthy controls.
HC RRMS PPMS Relapses
Spontaneous apoptosis
CD4+ T cells 11.1 (4.5) 13.8 (5.2) 17.2 (10.4) 15.1 (7.2)
CD8+ T cells 20.7 (8.3) 24.3 (10.1) 27.2 (13.7) 20.3 (8.0)
AICD
CD4+ T cells 29.9 (12.2) 25.4 (14.0) 27.5 (16.6) 30.2 (10.0)
CD8+ T cells 39.3 (11.5) 26.5 (11.6)⁎ 33.8 (17.5) 35.9 (15.4)
Data are presented as mean (SD). HC: healthy control. RRMS: patients with relapsing–
remitting multiple sclerosis in clinical remission. PPMS: patients with primary
progressive multiple sclerosis. Relapses: patients with relapsing–remitting multiple
sclerosis in relapse.
⁎ p b 0.05 compared to HC.(76.0% in HC and 67.0 in RRMS patients; p = 0.001) (Fig. 2B). A repre-
sentative ﬂow cytometry staining of Fas in HC and patients with RRMS
is shown in Supplementary Fig. 1. Finally, the percentage of T cells ex-
pressing Fas was similar between RRMS patients in clinical remission
and RRMS patients in relapse (Fig. 2C).3.3. Caspase 3 activation is defective in MS patients
To unravel themolecularmechanisms implicated in the impaired re-
sponse to PHA-induced apoptosis, caspase 3 expression and activation
were next evaluated in PBMC from HC and MS patients following PHA
stimulation. As shown in Fig. 3, the full or inactive form of caspase 3
was clearly more expressed in MS patients compared to HC, while ex-
pression of the cleaved or active form was diminished in MS patients,
particularly in the RRMS group. This observation implies an impairment
in caspase 3 activation in patients with RRMS.
Fig. 3.Caspase 3 expression and activation inHC andMS patients after PHA stimulation. (A)Western blot represents the expression of the full-length caspase 3 (inactive form or pro-form)
and the cleaved caspase 3 (active form) in 3 individuals per group. The ﬁgure is representative of a total of nine individuals per group. β-Actin was used as a housekeeping protein.
(B) Quantiﬁcation of the full-length caspase 3 and the 19 kDa cleaved form in the different groups normalized by β-actin expression. Error bars represent standard error of the mean.
*p b 0.05 in respect to HC. HC: healthy control. RRMS: relapsing–remitting multiple sclerosis in clinical remission. PPMS: primary progressive multiple sclerosis.
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Activation-induced cell death is one of the main mechanisms regu-
lating immune homeostasis, which is known to be altered in different
autoimmune diseases including MS (Zhang et al., 2004). The fact that
some MS therapies known to have beneﬁcial effects in the disease act
through an increase of apoptosis in T lymphocytes reinforces the rele-
vance of this process in MS pathogenesis (Rieks et al., 2003; Chan
et al., 2005; Ruggieri et al., 2006).
In the present work, we provide new insight into the apoptotic pro-
cess of T lymphocytes in MS patients. We investigated spontaneous ap-
optosis and AICD in T cells from different clinical forms and activity
phases of thedisease. The results of ourwork are in agreementwithpre-
vious reports indicating an impaired induction of apoptosis in peripher-
al T lymphocytes from MS patients (Sharief, 2000; Petcu et al., 2006;
Julia et al., 2009). In addition to this observation, we found that AICD
was mainly altered in patients with RRMS in clinical remission and it
was not affected in patients with PPMS or RRMS patients during re-
lapses, pointing to different pathogenic mechanisms underlying the dif-
ferent clinical forms of MS.
Regarding spontaneous apoptosis, previous studies have reported
signiﬁcantly increased spontaneous ex vivo apoptosis in MS patients
compared toHC (Prieto et al., 2006; Garcia-Merino et al., 2009). Howev-
er, in our study the percentage of T lymphocytes undergoing spontane-
ous apoptosis did not differ between groups. The discrepancy might be
due to differences in the clinical activity of MS patients included in the
studies. Thus, whereas in previous studies the increase in spontaneous
apoptosis was more evident in patients with aggressive phenotypes
(more than 2 relapses in the two previous years), in our study RRMSpa-
tients had a more benign disease course as revealed by the low number
of relapses in the two years preceding blood extraction (0.4).
When exploring further themechanismsunderlying the impairment
of AICD observed in RRMS patients, we found that Fas expression, a
death receptor known to be important in AICD (Ju et al., 1995), was sig-
niﬁcantly reduced in T cells from MS patients, differences that wereprimarily driven by the RRMS group in clinical remission. Fas function
has been reported to be deﬁcient in T cells from MS patients (Comi
et al., 2000). Previous studies evaluating Fas expression in T lympho-
cytes fromMS patients revealed higher expression in MS patients com-
pared to controls and increased expression in MS patients during
relapses and in patients with the secondary progressive form of MS
(Ichikawa et al., 1996; Bilinska et al., 2001; Bilinska et al., 2003.) Another
study comparing Fas expression in T cells from RRMS patients in remis-
sion and HC resulted in no signiﬁcant differences between these two
groups (Bilinska et al., 2001), ﬁnding that is in disagreement with our
study andmay also be explained by differences in the clinical character-
istics of patients. RRMS patients in remission included in the study by
Bilinska et al. had more aggressive clinical phenotypes compared with
the more benign disease course observed for this group of patients in
our study.
Anothermechanism thatmight be involved in the failure of AICD ob-
served in RRMS patients is the activation of caspases. Caspases are
cysteine-aspartic acid proteasesmediating the cellular events that ﬁnal-
ly lead to apoptosis. Caspase 3 is an executioner caspase activated by
cleavage at the end of the apoptotic signaling cascade. Following PHA
stimulation, we observed that in control individuals, caspase 3 was nor-
mally activated whereas in patients with MS caspase 3 activation was
clearly deﬁcient. This ﬁnding was associated with a signiﬁcant increase
in the expression of the full length or inactive form of caspase 3, which
may be interpreted as a result of an impaired cleavagewhich leads to ac-
cumulation of the full-length caspase 3 or as an unsuccessful attempt to
restore normal caspase 3 function by incrementing its expression. This
failure in caspase 3 activationmay in part be responsible for the impair-
ment of AICD observed in RRMS patients.
In conclusion, our results point to a differential apoptotic behavior of
the clinical forms of MS. T lymphocytes from patients with the RRMS
form of the disease seem to bemore resistant to the AICD process com-
pared with control individuals. In contrast, AICD was not impaired in
T lymphocytes from patients with the PPMS form of the disease or
patients with RRMS whose blood was collected at the time of acute
55M. Moreno et al. / Journal of Neuroimmunology 272 (2014) 51–55exacerbations. These ﬁndings may possibly reﬂect differences in the
pathogenicmechanismsunderlying the various clinical forms and activ-
ity phases of the disease. In patients with RRMS, both a reduced expres-
sion of Fas and defective activation of caspase 3 are potential molecular
mechanisms associated with the failure of AICD observed in this group
of MS patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jneuroim.2014.04.007.
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